Form 4: Neuraxis CFO Granted 75,231 Restricted Stock Units

Neuraxis, Inc. Chief Financial Officer Timothy Henrichs was granted 75,231 restricted stock units, vesting over three years.

Summary

• Timothy Robert Henrichs, Chief Financial Officer of Neuraxis, INC (NRXS), was granted 75,231 Restricted Stock Units (RSUs).
• The transaction date for the RSU grant was January 22, 2026.
• These RSUs were granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
• Each RSU represents one share of common stock, with an implied value of $4.63 per RSU.
• The RSUs will vest in three equal annual installments over a three-year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The RSU grant aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing performance and retention.
• The grant is part of a structured incentive plan, indicating a commitment to executive compensation and talent retention.

Negatives

• The issuance of RSUs, upon vesting, will result in a slight dilution of existing shareholder equity, though this is a standard practice for executive compensation.

Future Outlook

The RSUs are scheduled to vest in three equal annual installments over a three-year period, indicating a future commitment to the CFO's compensation structure.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation across the biotechnology and pharmaceutical industries, aiming to align management incentives with long-term company performance and shareholder value creation. This grant to Neuraxis's CFO is consistent with typical compensation practices for publicly traded companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice, comparable to companies like Moderna (MRNA) or Pfizer (PFE) which also utilize equity-based incentives to retain and motivate key personnel.
• A three-year vesting schedule is typical for RSU grants, similar to programs seen at companies such as Biogen (BIIB) or Gilead Sciences (GILD), ensuring long-term commitment from executives.

Stakeholder Impact

• Shareholders: Potential for slight dilution upon vesting, but also increased alignment of management's interests with long-term shareholder value.
• Employees: Reinforces the company's compensation structure for key executives, potentially signaling stability in leadership.

Next Steps

• The RSUs will vest in three equal annual installments over a three-year period, starting from the grant date of January 22, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to a key executive, which is a standard compensation practice. While it aligns management's interests with shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Neuraxis, NRXS, Restricted Stock Units, RSU, CFO compensation, executive compensation, insider transaction, Form 4, equity grant, stock incentive plan